nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.02.2013 | Original article

Hypoxia-related molecules HIF-1α, CA9, and osteopontin

Predictors of survival in patients with high-grade glioma

verfasst von: O.P. Erpolat, MD, P.U. Gocun, MD, M. Akmansu, MD, G. Ozgun, MD, G. Akyol, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A high expression of hypoxia-inducible factor-1 alpha (HIF)-1α, carbonic anhydrase 9 (CA9), and osteopontin appears to be a strong prognostic indicator in many malignancies; however, their role is unclear in high-grade gliomas.

Patients and methods

HIF-1α, CA9, and osteopontin levels in tissue specimens of 92 patients with high-grade glioma were evaluated by immunohistochemistry.

Results

Patients with a high expression of cytoplasmic and nuclear HIF-1α, CA9, and osteopontin had significantly shorter overall survival. The expression results of these markers were combined to form a hypoxic profile, and high hypoxic scores (expression of two or three markers) were significantly correlated to poorer overall survival. In multivariate analysis, high hypoxic score-1 (cytoplasmic HIF-1α, CA9, and osteopontin) was the only independent negative prognostic factor for survival (p = 0.028).

Conclusion

Our results showed that a combination of hypoxic markers is more robust than a single marker for predicting survival in high-grade glioma. It may be necessary to utilize the hypoxic score in selecting patients for targeted therapy in the future.

Siker ML, Donahue BR, Vogelbaum MA et al (2008) Primary intracranial neoplasms. In: Halperin EC, Perez CA, Brady LW (eds) Principles and practice of radiation oncology, 5^th edn. Lippincott Williams&Wilkins, Philadelphia, pp 717–751

Jensen RL (2009) Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92:317–335PubMedCrossRef

Zagzag D, Lukyanov Y, Lan L et al (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86:1221–1232PubMedCrossRef

Said HM, Hagemann C, Staab A et al (2007) Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1α in human glioma in vitro and in vivo. Radiother Oncol 83:398–405PubMedCrossRef

Höckel M, Vaupel P (2001) Biological consequences of tumor hypoxia. Semin Oncol 28:36–41PubMedCrossRef

Le QT, Courter D (2008) Clinical biomarkers for hypoxia targeting. Cancer Met Rev 27:351–362CrossRef

Vordermark D, Brown JM (2003) Endogenous markers of tumor hypoxia. Strahlenther Onkol 179:801–811PubMedCrossRef

Staab A, Fleischer M, Loeffler J et al (2011) Small interfering RNA targeting HIF-1α reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. Strahlenther Onkol 187:252–259PubMedCrossRef

Le QT, Kong C, Lavori PW et al (2007) Expression and prognostic significance of a panel of tissue hypoxia markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69:167–175PubMedCrossRef

10.

Sreekanthreddy P, Srinivasan H, Kumar DM et al (2010) Identification of potential erum biomarkers of Glioblastoma: Serum Osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 19:1409–1422PubMedCrossRef

11.

Birner P, Schindl M, Obermair A et al (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early stage invasive cervical cancer. Cancer Res 60:4693–4696PubMed

12.

Bos R, Groep P van der, Greijer AE et al (2003) Levels of hypoxia-inducible factor 1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573–1581PubMedCrossRef

13.

Schilling D, Bayer C, Emmerich K et al (2012) Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines. Strahlenther Onkol 188:353–358PubMedCrossRef

14.

Pennacchietti S, Michieli P, Galluzo M et al (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347–361PubMedCrossRef

15.

Wang Y, Yan W, Lu X et al (2011) Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 90:642–648PubMedCrossRef

16.

Colin C, Baeza N, Bartoli C et al (2006) Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using supression subtractive hybridization. Oncogene 25:2818–2826PubMedCrossRef

17.

Coppola D, Szabo M, Boulware D et al (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histogenesis. Clin Cancer Res 10:184–190PubMedCrossRef

18.

Matusan K, Dordevic G, Stipic D et al (2006) Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 94:325–331PubMedCrossRef

19.

Saitoh Y, Kuratsu J, Takeshima H et al (1995) Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 72:55–63PubMed

20.

Scott CB, Scarantino C, Urtasun R et al (1998) Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 92–06. Int J Radiat Oncol Biol Phys 40:51–55PubMedCrossRef

21.

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732PubMedCrossRef

22.

Irie N, Matsuo T, Nagata I (2004) Protocol of radiotherapy for glioblastome according to to the expression of HIF-1. Brain Tumor Pathol 21:1–6PubMedCrossRef

23.

Zagzag D, Zhang H, Scalzitti JM et al (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606–2618PubMedCrossRef

24.

Korkolopoulou P, Perdiki M, Tyhmara I et al (2007) Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol 38:629–638PubMedCrossRef

25.

Wykoff CC, Beasley N, Watson PH et al (2001) Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 158:1011–1019PubMedCrossRef

26.

Matusan-IIijas KM, Behrem S, Jonjie N et al (2008) Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res 14:293–298CrossRef

27.

Atai NA, Bansal M, Lo C et al (2010) Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology 132:39–48PubMedCrossRef

28.

Wang Y, Yan W, Lu X et al (2011) Overexpression of osteopontin induces angiogenesis of endothelial progenitor cell via the avβ3/P13K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 90:642–648PubMedCrossRef

29.

Jang T, Savarase T, Low HP et al (2006) Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. Am J Pathol 168:1676–1685PubMedCrossRef

30.

Ding Q, Stewart J Jr, Prince CW et al (2002) Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 62:5336–5343PubMed

31.

Cefaro GA, Genovesi D, Vinciguerra A et al (2011) Prognostic impact of hemoglobin level and other factors in patients with high grade glioma treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10 year experience at a sinle institution. Strahlanther Onkol 187:778–783CrossRef

32.

Hui EP, Chan ATC, Pezzella F et al (2002) Co-expression of hypoxia-inducible factors 1α and 2α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8:2595–2604PubMed

Titel: Hypoxia-related molecules HIF-1α, CA9, and osteopontin
Predictors of survival in patients with high-grade glioma
verfasst von: O.P. Erpolat, MD
P.U. Gocun, MD
M. Akmansu, MD
G. Ozgun, MD
G. Akyol, MD
Publikationsdatum: 01.02.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 2/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0262-5

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Hypoxia-related molecules HIF-1α, CA9, and osteopontin

Predictors of survival in patients with high-grade glioma

Abstract

Purpose

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Purpose

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Lokale Kontrolle bei T3-Rektumkarzinomen

Abstracts der 29. Jahrestagung der Österreichischen Gesellschaft für Radioonkologie, Radiobiologie und Medizinische Radiophysik (ÖGRO 2012)

Karzinom des Ösophagus und des gastroösophagealen Übergangs

Diffusion-weighted MRI in locally advanced rectal cancer

Kein Vorteil durch FOLFOX4 für ältere und Stadium-II-Kolonkarzinompatienten

Intraoperative EBRT and resection for renal cell carcinoma

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie